These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34984932)

  • 1. Industry 4.0 Technologies for the Manufacturing and Distribution of COVID-19 Vaccines.
    Sarfraz A; Sarfraz Z; Sarfraz M; Abdul Razzack A; Bano S; Singh Makkar S; Thevuthasan S; Paul T; Khawar Sana M; Azeem N; Felix M; Cherrez-Ojeda I
    J Prim Care Community Health; 2022; 13():21501319211068638. PubMed ID: 34984932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redressing COVID-19 vaccine inequity amidst booster doses: charting a bold path for global health solidarity, together.
    Rackimuthu S; Narain K; Lal A; Nawaz FA; Mohanan P; Essar MY; Charles Ashworth H
    Global Health; 2022 Feb; 18(1):23. PubMed ID: 35193616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future.
    Pilkington V; Keestra SM; Hill A
    Front Public Health; 2022; 10():821117. PubMed ID: 35321196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries.
    Peacocke EF; Heupink LF; Frønsdal K; Dahl EH; Chola L
    BMJ Open; 2021 Sep; 11(9):e049505. PubMed ID: 34593496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccine challenges: What have we learned so far and what remains to be done?
    Forman R; Shah S; Jeurissen P; Jit M; Mossialos E
    Health Policy; 2021 May; 125(5):553-567. PubMed ID: 33820678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Vaccine Diplomacy and Equitable Access to Vaccines Amid Ongoing Pandemic.
    Sharun K; Dhama K
    Arch Med Res; 2021 Oct; 52(7):761-763. PubMed ID: 33941393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation.
    McGoldrick M; Gastineau T; Wilkinson D; Campa C; De Clercq N; Mallia-Milanes A; Germay O; Krishnan J; Van Ooij M; Thien MP; Mlynarczyk PJ; Saltus E; Wauters F; Juvin P; Clenet D; Basso A; Dellepiane N; Pagliusi S; Collaço de Moraes Stávale M; Sivaramakrishnan VH; Desai S
    Vaccine; 2022 Feb; 40(9):1223-1230. PubMed ID: 35180994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization.
    Hayman B; Dennehy M
    Vaccine; 2021 Aug; 39(36):5153-5161. PubMed ID: 34362602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Vaccine Development to Vaccination.
    Pandey A; Belbase P; Parajuli A
    J Nepal Health Res Counc; 2021 Jan; 18(4):807-809. PubMed ID: 33510536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 2: vaccine technologies].
    Monschein T; Zrzavy T; Löbermann M; Winkelmann A; Berger T; Rommer P; Hartung HP; Zettl UK
    Nervenarzt; 2021 Dec; 92(12):1283-1292. PubMed ID: 34232358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccine and the cold chain implications for global adoption.
    Das MK
    Indian J Public Health; 2021; 65(3):307-310. PubMed ID: 34558497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustainable vaccine manufacturing in low- and middle-Income countries.
    Hayman B; Kumar Suri R; Downham M
    Vaccine; 2022 Nov; 40(50):7288-7304. PubMed ID: 36334966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to accelerate the supply of vaccines to all populations worldwide? Part I: Initial industry lessons learned and practical overarching proposals leveraging the COVID-19 situation.
    McGoldrick M; Gastineau T; Wilkinson D; Campa C; Clercq N; Mallia-Milanes A; Germay O; Krishnan J; Van Ooij M; Thien MP; Mlynarczyk PJ; Saltus E; Juvin P; Clenet D; Basso A; Dellepiane N; Pagliusi S; de Moraes Stávale MC; Sivaramakrishnan VH; Desai S
    Vaccine; 2022 Feb; 40(9):1215-1222. PubMed ID: 35180993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility.
    Eccleston-Turner M; Upton H
    Milbank Q; 2021 Jun; 99(2):426-449. PubMed ID: 33650737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is COVID-19 vaccine inequality undermining the recovery from the COVID-19 pandemic?
    Suárez-Álvarez A; López-Menéndez AJ
    J Glob Health; 2022 May; 12():05020. PubMed ID: 35604879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach.
    Kim D; Pekgün P; Yildirim İ; Keskinocak P
    Vaccine; 2021 Nov; 39(47):6876-6882. PubMed ID: 34688498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Race for Global Equitable Access to COVID-19 Vaccines.
    Md Khairi LNH; Fahrni ML; Lazzarino AI
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.